Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus
-
Published:2023-08
Issue:1
Volume:511
Page:227-234
-
ISSN:1607-6729
-
Container-title:Doklady Biochemistry and Biophysics
-
language:en
-
Short-container-title:Dokl Biochem Biophys
Author:
Cheldieva F. A.,Reshetnyak T. M.,Shumilova A. A.,Nurbaeva K. S.,Cherkasova M. V.,Lila A. M.,Nasonov E. L.
Abstract
Abstract
The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors. To validate GAPSS in a cohort of patients with systemic lupus erythematosus in Russia. 115 patients with SLE were included in the study, including 51 (44%) patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS), 14 (12%) SLE patients with aPL, and 50 (44%) patients with SLE. There was a history of thrombosis in 58 (50%) out of 115 patients; of them, 14 (24%) had arterial thrombosis, 29 (50%) had venous thrombosis, and 15 (26%) had combined thrombosis. Pregnancy against the background of the disease occurred in 43 women included in the study. Of them, 29 (67%) had obstetric pathology. Patients with thrombosis and obstetric pathology had a GAPSS score of 7.17 ± 5.64 versus 4.48 ± 4.55 without these manifestations (p = 0.0003). There was a significant association between GAPSS levels and thrombosis: patients with thrombosis had a GAPSS of 7.31 ± 5.70, those without thrombosis—4.00 ± 4.81 (p = 0.001). GAPPS values were higher in arterial thrombosis compared to venous thrombosis (10.40 ± 25.30 versus 5.82 ± 5.28, p = 0.01). GAPSS levels ≥ 6 and ≥10 were analyzed to select GAPSS values at which a high risk of recurrent thrombosis and/or obstetric pathology could be indicated. All GAPSS levels had a significant association with clinical manifestations of APS. The quality of GAPSS by ROC analysis showed an area under the curve (AUC) for GAPSS of 0.697. GAPSS can be used to assess the risk of recurrence or development of thrombosis and/or obstetric pathology in patients with SLE in the Russian Federation. The GAPSS ≥6 values should be used to stratify patients with SLE into high risk group for recurrence of vascular complications. Further prospective follow-up is needed to confirm the value of GAPSS.
Publisher
Pleiades Publishing Ltd
Subject
General Chemistry,Biochemistry,General Medicine,Biophysics
Reference26 articles.
1. Reshetnyak, T.M., Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture), Nauchno-Prakt.
Revmatol., 2014, vol. 52, no. 1, pp. 56–71. 2. Miyakis, S., Lockshin, M.D., Atsumi, T., et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 2006, vol. 4, no. 2, pp. 295–306. 3. Radin, M., Ugolini-Lopes, M.R., Sciascia, S., and Andrade, D., Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management, Semin. Arthritis Rheum., 2018, vol. 48, no. 1, pp. 117–120. https://doi.org/10.1016/j.semarthrit.2017.12.006 4. Alarcon-Segovia, D., Pe’rez-Ruiz, A., and Villa, A.R., Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus, J. Autoimmun., 2000, vol. 15, no. 2, pp. 157–161. 5. Amigo, M.C., Prognosis in antiphospholipid syndrome, Rheum. Dis. Clin. North Am., 2001, vol. 27, no. 3, pp. 661–669.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|